Company intelligence / Profile preview

Tagomics

Little Abington, Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

Tagomics is developing a multiomic biomarker discovery and diagnostic platform (Interlace) that integrates genomics, epigenomics, and fragmentomics to provide comprehensive disease profiling, with an initial focus on cancer diagnostics and early detection. The platform is being customized for colorectal cancer detection in partnership with Innovate UK, and is being advanced toward clinical application, but there are no reported clinical trial results or regulatory approvals yet.

Therapeutic areas: OncologyOther
Modalities: Biomarker diagnostic platform
Industry: Molecular Diagnostics

Partnerships

Agilent (co-marketing agreement)

Beyond the preview

Go deeper on Tagomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tagomics.

Explore the full profile